# ClinicalTrials.gov record NCT05368857

> PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide.

- Evidence object: `story:clinicaltrials-gov-nct05368857-afamelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05368857-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05368857-afamelanotide-v1.json
- Content SHA-256: `bbc9f065e9cbb2e19a6ae0131df039c0aed738eb36dea15d726ac2afc0255601`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05368857 ([`ctg-observation-nct05368857-2023-02-09-611811f36b54`](#source-ctg-observation-nct05368857-2023-02-09-611811f36b54))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct05368857-2023-02-09-611811f36b54`](#source-ctg-observation-nct05368857-2023-02-09-611811f36b54))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct05368857-2023-02-09-611811f36b54`](#source-ctg-observation-nct05368857-2023-02-09-611811f36b54))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05368857-2023-02-09-611811f36b54`](#source-ctg-observation-nct05368857-2023-02-09-611811f36b54))

## Sources

<a id="source-ctg-observation-nct05368857-2023-02-09-611811f36b54"></a>
- **ClinicalTrials.gov record NCT05368857 · retained source version 2023-02-09:611811f36b54c6aecb20865e28e9a497b5b695f9023c3de864ab644b344806b1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05368857) (`ctg-observation-nct05368857-2023-02-09-611811f36b54`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05368857." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05368857-afamelanotide-v1.json SHA-256: bbc9f065e9cbb2e19a6ae0131df039c0aed738eb36dea15d726ac2afc0255601.